The antibody recognizes the typical amyloid deposits in brains of patients suffering from the disease. This antibody has been developed against the carboxy terminal extracellular sequence of the mutated BRI protein.
ITM2B
Reactivity: Human
ELISA
Host: Rabbit
Polyclonal
Biotin
Application Notes
Suitable for Immunohistochemistry on frozen sections. Suggested positive control: pathological brain sections. (Not recommended in Western blots). Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions
For Research Use only
Concentration
1.0 mg /ml
Buffer
PBS, pH 7.2, containing 0.09 % sodium azide as preservative.
Preservative
Sodium azide
Precaution of Use
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handling Advice
Avoid repeated freezing and thawing.
Storage
4 °C/-20 °C
Storage Comment
Store the antibody at 2-8 °C (Lyophilized) or reconstituted in small aliquots at -20 °C.
The mutated BRI protein (ITM2B) was identified in patients with familial British dementia. The unusual 277 residue precursor protein releases a 34-residue amyloidogenic peptide by the action of the protease furin, leading to the deposition of a protein fragment that seems to be involved in the pathogenesis of familial British dementia.Synonyms: BRI, BRI2, ITM2B, Integral membrane protein 2B, Transmembrane protein BRI